Published in Biophys J on July 11, 2008
Probing carbohydrate product expulsion from a processive cellulase with multiple absolute binding free energy methods. J Biol Chem (2011) 1.03
Dissecting DNA-histone interactions in the nucleosome by molecular dynamics simulations of DNA unwrapping. Biophys J (2011) 0.99
Absolute FKBP binding affinities obtained via nonequilibrium unbinding simulations. J Chem Phys (2009) 0.94
A comparative approach linking molecular dynamics of altered peptide ligands and MHC with in vivo immune responses. PLoS One (2010) 0.94
Overcoming dissipation in the calculation of standard binding free energies by ligand extraction. J Comput Chem (2013) 0.89
T-cell epitope prediction and immune complex simulation using molecular dynamics: state of the art and persisting challenges. Immunome Res (2010) 0.84
Structure-Based, Rational Design of T Cell Receptors. Front Immunol (2013) 0.84
Molecular analysis of the interaction between staphylococcal virulence factor Sbi-IV and complement C3d. Biophys J (2014) 0.83
Large scale characterization of the LC13 TCR and HLA-B8 structural landscape in reaction to 172 altered peptide ligands: a molecular dynamics simulation study. PLoS Comput Biol (2014) 0.83
Optimization of an elastic network augmented coarse grained model to study CCMV capsid deformation. PLoS One (2013) 0.80
The effect of different force applications on the protein-protein complex Barnase-Barstar. Biophys J (2009) 0.78
Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex. J Mol Model (2013) 0.78
Early relaxation dynamics in the LC 13 T cell receptor in reaction to 172 altered peptide ligands: a molecular dynamics simulation study. PLoS One (2013) 0.78
Computational Studies of Molecular Permeation through Connexin26 Channels. Biophys J (2016) 0.77
Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVβ20-1, altering pHLA recognition. PLoS One (2013) 0.77
Computer applications for prediction of protein-protein interactions and rational drug design. Adv Appl Bioinform Chem (2009) 0.77
Quantitative Analysis of the Association Angle between T-cell Receptor Vα/Vβ Domains Reveals Important Features for Epitope Recognition. PLoS Comput Biol (2015) 0.76
In silico insights into protein-protein interactions and folding dynamics of the saposin-like domain of Solanum tuberosum aspartic protease. PLoS One (2014) 0.76
The Dynamics of the Human Leukocyte Antigen Head Domain Modulates Its Recognition by the T-Cell Receptor. PLoS One (2016) 0.75
TCR triggering by pMHC ligands tethered on surfaces via poly(ethylene glycol) depends on polymer length. PLoS One (2014) 0.75
GROMACS: fast, flexible, and free. J Comput Chem (2005) 27.22
Canonical dynamics: Equilibrium phase-space distributions. Phys Rev A Gen Phys (1985) 26.82
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Ligand binding: molecular mechanics calculation of the streptavidin-biotin rupture force. Science (1996) 8.19
How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol (2006) 7.57
Optimized Monte Carlo data analysis. Phys Rev Lett (1989) 7.03
Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature (1996) 6.20
Equilibrium information from nonequilibrium measurements in an experimental test of Jarzynski's equality. Science (2002) 5.76
Unfolding of titin immunoglobulin domains by steered molecular dynamics simulation. Biophys J (1998) 5.01
Free energy reconstruction from nonequilibrium single-molecule pulling experiments. Proc Natl Acad Sci U S A (2001) 4.56
Calculating potentials of mean force from steered molecular dynamics simulations. J Chem Phys (2004) 3.81
Energetics of glycerol conduction through aquaglyceroporin GlpF. Proc Natl Acad Sci U S A (2002) 3.60
A structural basis for the selection of dominant alphabeta T cell receptors in antiviral immunity. Immunity (2003) 3.41
T-cell-receptor gene therapy. Nat Rev Immunol (2002) 3.31
Entropy production fluctuation theorem and the nonequilibrium work relation for free energy differences. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (1999) 3.25
Calculation of absolute protein-ligand binding free energy from computer simulations. Proc Natl Acad Sci U S A (2005) 3.21
Steered molecular dynamics investigations of protein function. J Mol Graph Model (2001) 3.04
Locally accessible conformations of proteins: multiple molecular dynamics simulations of crambin. Protein Sci (1998) 2.94
Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity (1999) 2.86
A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity (1996) 2.69
Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy. Biophys J (2004) 2.69
From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell (1999) 2.52
Comparison of efficiency and bias of free energies computed by exponential averaging, the Bennett acceptance ratio, and thermodynamic integration. J Chem Phys (2005) 2.31
Equilibrium free energies from nonequilibrium measurements using maximum-likelihood methods. Phys Rev Lett (2003) 2.30
On the calculation of absolute macromolecular binding free energies. Proc Natl Acad Sci U S A (2002) 2.17
Kinetic discrimination in T-cell activation. Proc Natl Acad Sci U S A (1996) 2.17
CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Nat Immunol (2003) 2.10
The impact of duration versus extent of TCR occupancy on T cell activation: a revision of the kinetic proofreading model. Immunity (2001) 2.02
Free energy surfaces from single-molecule force spectroscopy. Acc Chem Res (2005) 1.95
Forced detachment of the CD2-CD58 complex. Biophys J (2003) 1.92
Force spectroscopy of single biomolecules. Chemphyschem (2002) 1.73
Two different T cell receptors use different thermodynamic strategies to recognize the same peptide/MHC ligand. J Mol Biol (2005) 1.55
Structural and thermodynamic correlates of T cell signaling. Annu Rev Biophys Biomol Struct (2001) 1.49
Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: implications for TCR signaling. Immunity (2000) 1.48
Comparison of free energy methods for molecular systems. J Chem Phys (2006) 1.34
Rare events and the convergence of exponentially averaged work values. Phys Rev E Stat Nonlin Soft Matter Phys (2006) 1.33
Comparison between computational alanine scanning and per-residue binding free energy decomposition for protein-protein association using MM-GBSA: application to the TCR-p-MHC complex. Proteins (2007) 1.25
The efficiency of antigen recognition by CD8+ CTL clones is determined by the frequency of serial TCR engagement. J Immunol (1998) 1.22
High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J Mol Biol (2004) 1.21
CD8+ cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimers. J Biol Chem (2005) 1.18
Potentials of mean force for acetylcholine unbinding from the alpha7 nicotinic acetylcholine receptor ligand-binding domain. J Am Chem Soc (2006) 1.15
Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol (2002) 1.11
Efficient use of nonequilibrium measurement to estimate free energy differences for molecular systems. J Comput Chem (2004) 1.08
Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol (2003) 1.07
Binding free energy differences in a TCR-peptide-MHC complex induced by a peptide mutation: a simulation analysis. J Mol Biol (2002) 1.05
A comprehensive calorimetric investigation of an entropically driven T cell receptor-peptide/major histocompatibility complex interaction. Biophys J (2007) 1.04
Strategic mutations in the class I major histocompatibility complex HLA-A2 independently affect both peptide binding and T cell receptor recognition. J Biol Chem (2004) 0.99
MHC-peptide binding is assisted by bound water molecules. J Mol Biol (2004) 0.98
Single-ensemble nonequilibrium path-sampling estimates of free energy differences. J Chem Phys (2004) 0.95
Biased sampling of nonequilibrium trajectories: can fast switching simulations outperform conventional free energy calculation methods? J Phys Chem B (2005) 0.90
T cell receptor binding transition states and recognition of peptide/MHC. Biochemistry (2007) 0.89
Work distribution for the adiabatic compression of a dilute and interacting classical gas. Phys Rev E Stat Nonlin Soft Matter Phys (2007) 0.84
The Jarzynski identity derived from general Hamiltonian or non-Hamiltonian dynamics reproducing NVT or NPT ensembles. J Chem Phys (2006) 0.82
On the calculation of velocity-dependent properties in molecular dynamics simulations using the leapfrog integration algorithm. J Chem Phys (2007) 0.82
Statistical mechanical derivation of Jarzynski's identity for thermostated non-Hamiltonian dynamics. Phys Rev Lett (2006) 0.78
A proof of Jarzynski's nonequilibrium work theorem for dynamical systems that conserve the canonical distribution. J Chem Phys (2006) 0.76
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10
SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem (2011) 2.74
SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res (2011) 2.46
Inhibition of the shade avoidance response by formation of non-DNA binding bHLH heterodimers. EMBO J (2009) 2.20
The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem (2007) 1.89
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58
Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta (2007) 1.50
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol (2008) 1.50
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother (2013) 1.42
Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab (2003) 1.41
Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. J Virol (2010) 1.40
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
Structural prediction of peptides bound to MHC class I. J Mol Biol (2005) 1.33
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol (2013) 1.31
Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res (2013) 1.25
Fast docking using the CHARMM force field with EADock DSS. J Comput Chem (2011) 1.25
Comparison between computational alanine scanning and per-residue binding free energy decomposition for protein-protein association using MM-GBSA: application to the TCR-p-MHC complex. Proteins (2007) 1.25
Model structure of human APOBEC3G. PLoS One (2007) 1.24
Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2010) 1.22
CD3 delta establishes a functional link between the T cell receptor and CD8. J Biol Chem (2002) 1.20
CD8+ cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimers. J Biol Chem (2005) 1.18
A combined computational and functional approach identifies new residues involved in pH-dependent gating of ASIC1a. J Biol Chem (2010) 1.17
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem (2012) 1.16
The V-ATPase proteolipid cylinder promotes the lipid-mixing stage of SNARE-dependent fusion of yeast vacuoles. EMBO J (2011) 1.12
Functional dynamics of PDZ binding domains: a normal-mode analysis. Biophys J (2005) 1.11
Shaping the interaction landscape of bioactive molecules. Bioinformatics (2013) 1.09
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. Melanoma Res (2014) 1.08
Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation. J Virol (2006) 1.08
Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol (2003) 1.07
Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol (2012) 1.06
Structural and functional interaction sites between Na,K-ATPase and FXYD proteins. J Biol Chem (2004) 1.03
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol (2012) 1.01
EADock: docking of small molecules into protein active sites with a multiobjective evolutionary optimization. Proteins (2007) 1.00
Defining and searching for structural motifs using DeepView/Swiss-PdbViewer. BMC Bioinformatics (2012) 1.00
SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest (2013) 1.00
The fourth transmembrane segment of the Na,K-ATPase alpha subunit: a systematic mutagenesis study. J Biol Chem (2004) 0.99
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer (2011) 0.99
SwissSidechain: a molecular and structural database of non-natural sidechains. Nucleic Acids Res (2012) 0.99
SwissBioisostere: a database of molecular replacements for ligand design. Nucleic Acids Res (2012) 0.98
Docking, virtual high throughput screening and in silico fragment-based drug design. J Cell Mol Med (2009) 0.98
Sequence determinants of a microtubule tip localization signal (MtLS). J Biol Chem (2012) 0.95
Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A (2008) 0.94
How T cell receptors interact with peptide-MHCs: a multiple steered molecular dynamics study. Proteins (2011) 0.94
Blind docking of 260 protein-ligand complexes with EADock 2.0. J Comput Chem (2009) 0.93
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. J Immunol (2007) 0.92
Molecular basis of leukocyte rolling on PSGL-1. Predominant role of core-2 O-glycans and of tyrosine sulfate residue 51. J Biol Chem (2002) 0.91
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncol Rep (2012) 0.89
Expanding molecular modeling and design tools to non-natural sidechains. J Comput Chem (2012) 0.89
RNA pentaloop structures as effective targets of regulators belonging to the RsmA/CsrA protein family. RNA Biol (2013) 0.89
Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor alpha helix 12 dynamic behavior. J Biol Chem (2007) 0.87
Frequent MAGE mutations in human melanoma. PLoS One (2010) 0.87
Unique spectrum of activity of prosimian TRIM5alpha against exogenous and endogenous retroviruses. J Virol (2011) 0.87
TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires. PLoS One (2011) 0.85
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition. J Med Chem (2012) 0.85
In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. Biopharm Drug Dispos (2008) 0.85
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer (2013) 0.84
Homology-based identification of capsid determinants that protect HIV1 from human TRIM5α restriction. J Biol Chem (2010) 0.84
Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother (2007) 0.83
Use of the FACTS solvation model for protein-ligand docking calculations. Application to EADock. J Mol Recognit (2010) 0.83
Structural assessment of single amino acid mutations: application to TP53 function. Hum Mutat (2006) 0.83
The peroxisomal enzyme L-PBE is required to prevent the dietary toxicity of medium-chain fatty acids. Cell Rep (2013) 0.81
Improving binding affinity and stability of peptide ligands by substituting glycines with D-amino acids. Chembiochem (2013) 0.81
iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J Chem Inf Model (2014) 0.81
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med (2014) 0.80
Identification of human IKK-2 inhibitors of natural origin (part I): modeling of the IKK-2 kinase domain, virtual screening and activity assays. PLoS One (2011) 0.80
Local alignment refinement using structural assessment. PLoS One (2008) 0.80
Structure-function characterization and optimization of a plant-derived antibacterial peptide. Antimicrob Agents Chemother (2005) 0.80
Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. Proc Natl Acad Sci U S A (2011) 0.80
Protein pocket and ligand shape comparison and its application in virtual screening. J Comput Aided Mol Des (2013) 0.79
The caveolin-binding motif of the pathogen-related yeast protein Pry1, a member of the CAP protein superfamily, is required for in vivo export of cholesteryl acetate. J Lipid Res (2014) 0.79
Identification of human IKK-2 inhibitors of natural origin (Part II): in Silico prediction of IKK-2 inhibitors in natural extracts with known anti-inflammatory activity. Eur J Med Chem (2011) 0.79
Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships. PLoS One (2013) 0.78
Docking to heme proteins. J Comput Chem (2009) 0.78
Access of extracellular cations to their binding sites in Na,K-ATPase: role of the second extracellular loop of the alpha subunit. J Gen Physiol (2006) 0.77
[A practical guide for the management of gliomas]. Bull Cancer (2007) 0.77
T-cell receptors binding orientation over peptide/MHC class I is driven by long-range interactions. PLoS One (2012) 0.77
Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. PLoS One (2013) 0.76
The fourth extracellular loop of the alpha subunit of Na,K-ATPase. Functional evidence for close proximity with the second extracellular loop. J Biol Chem (2008) 0.76
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable? Lung Cancer (2013) 0.76
Fourier transform convolution integrals applied to generalized Born molecular volume. J Comput Chem (2010) 0.76
[Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"]. Rev Med Suisse (2016) 0.75
[Present chemoprevention and future vision]. Rev Med Suisse (2005) 0.75
Successes and limitations of targeted cancer therapy in melanoma. Prog Tumor Res (2014) 0.75
The Binding Mode of N-Hydroxyamidines to Indoleamine 2,3-Dioxygenase 1 (IDO1). Biochemistry (2017) 0.75
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Res (2017) 0.75
Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity. J Immunol (2006) 0.75
A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation. Chembiochem (2004) 0.75
[New therapeutic weapons in stage IV melanoma]. Rev Med Suisse (2013) 0.75
A natural structural variant of the mouse TCR beta-chain displays intrinsic receptor function and antigen specificity. J Immunol (2006) 0.75